Jonathan W. Goldman, MD / Misty Dawn Shields, MD, PhD - The Emerging Nuances of Extensive-Stage SCLC Treatment: Individualizing Care in the Immunotherapy Era

What this episode covers

For the complete activity, including supporting material, please visit https://www.peervoice.com/KBA860. Presented by Jonathan W. Goldman, MD and Misty Dawn Shields, MD, PhD. Learning Objectives: Recall the current evidence base and guideline recommendations for the use of immunotherapy in small cell lung cancer (SCLC); Evaluate the rationale, evidence, and implications of emerging strategies for treatment of extensive-stage (ES)-SCLC, including use of combination therapy in the maintenance phase of first-line treatment; Identify relevant patient and disease-specific considerations that may guide contemporary therapy planning and increase the importance of shared clinical decision-making for ES-SCLC.

Distinct summary based on available episode metadata or transcript content.